The advent of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) has revolutionized the management of type 2 diabetes (T2D), offering not only improved glycemic control and a beneficial decrease in cardiovascular disease (CVD) risks but also a favorable effect on significant weight loss.1, 2, 3. Here, GLP1R is linked to type 2 diabetes mellitus.